Skip to main content

Advertisement

Table 1 Clinical characteristics of acute lymphoblastic leukemia survivors

From: Identification of genetic association between cardiorespiratory fitness and the trainability genes in childhood acute lymphoblastic leukemia survivors

  Childhood ALL survivors Females Males
Total 239 120 119
Age at visit (y) 21.5 ± 6.1 21.5 ± 6.3 21.6 ± 6.0
Age at cancer diagnosis (y) 6.3 ± 4.6 6.2 ± 4.4 6.4 ± 4.7
Time from the end of the treatment (y) 13.0 ± 5.0 13.0 ± 5.3 12.9 ± 4.8
Weight (kg) 66.8 ± 16.4 63.7 ± 16.6 70.0 ± 15.7
Height (cm) 166.9 ± 10.0 160.3 ± 6.7 171.5 ± 9.6
\( \dot{\mathrm{V}} \)O2 peak (mL.kg− 1.min− 1) 32.6 ± 8.4 27.6 ± 6.5 36.9 ± 7.4*
Power at \( \dot{\mathrm{V}} \) O2 peak (W) 174.7 ± 55.3 133.5 ± 28.9 213.8 ± 45.0*
\( \dot{\mathrm{V}} \)O2 peak predicted (%) 85.7 ± 17.1 86.8 ± 18.3* 83.2 ± 15.4
Physical activity (min) 27.8 ± 29.4 24.9 ± 30.3 30.5 ± 28.4*
DOX (mg/m2) 182.8 ± 119.7 183.4 ± 121.9 182.2 ± 117.9
DEX (mg/m2) 2781.0 ± 440.0 2828.8 ± 374.4 2731.8 ± 499.4
  1. ALL acute lymphoblastic leukemia, DOX cumulative dose of doxorubicin, DEX cumulative dose of dexrazoxane. Physical activity variable represents minutes per day of moderate or intense leisure physical activities. Data are expressed as percentage or as means ± SD. *p < 0.05, Females versus Males